Fig. 3
From: Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment
Late-stage collagen-dense mammary tumor recruitment of myeloid cells is not altered. a Flow cytometry gates used to determine myeloid cells. b Percentage of CD45+ immune cells in wild-type (WT) and collagen-dense (COL) mammary tumors at 15 weeks (n = 6, each of which was an independent pair of age-matched littermate WT and COL mice). c Flow cytometry of CD45+CD3– cells comparing Ly6G to F4/80 in WT (left) and COL (right) mammary tumors. Purple number represents the number of total events in each graph. d Percentage of CD45+CD3-CD11b+ cells that are F4/80+ macrophages in WT and COL mice. e Flow cytometry of CD45+CD11b+CD3– cells comparing Ly6C to Ly6G in WT (left) and COL (right) mammary tumors; f the percentage of CD45+CD3-CD11b+ Ly6G+Ly6C+ neutrophils present. g Immunohistochemical analysis of WT (left) and COL (right) mammary tumors. Tumors were stained with Ly6G (1A8) in diaminobenzidine and counterstained with hematoxylin. Scare bar 50 um. h average number of Ly6G+ cells found in eight fields of view per tumor slide (n = 4)